REGN240927C1080000
- 1.45
- -0.56-27.86%
Regeneron Pharmaceuticals Newsroom
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,245
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,245
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,242
U.S. Stock Gold Rush | Stock prices have doubled this year! Streaming music service giant Spotify achieved 6 consecutive gains; can it rise another 14%? Netflix's stock price hits another all-time high, up nearly 50% this year.
USA construction machinery giant Caterpillar rose nearly 4% overnight, setting a new all-time high, with a cumulative increase of over 32% year to date.
Express News | Royal Bank of Canada has lowered the target price of regeneron pharmaceuticals from $1282.00 to $1252.00.
Regeneron Pharma Is Maintained at Outperform by RBC Capital
Regeneron Pharmaceuticals Worst Performer in the S&P 500 and Nasdaq 100 So Far Today -- Data Talk
Regeneron Pharmaceuticals Hits 7-week Low
Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1200 Price Target
Evercore Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,250
Evercore analyst Cory Kasimov maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,250.According to TipRanks data, the analyst has a success rate of 5
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Regeneron Downgraded at Leerink After Amgen's Court Win; Truist Defends
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $1,200 to $1,300
On Sep 24, major Wall Street analysts update their ratings for $Regeneron Pharmaceuticals(REGN.US)$, with price targets ranging from $1,200 to $1,300.Morgan Stanley analyst Terence Flynn maintains
This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
U.S. stock prospects | Wall Street sings praises! Tesla soared nearly 5%, reaching a two-month high; Chinese concept stocks stepping on the gas? Alibaba's stock price hits a one-year high, ke holdings skyrocketed by over 7% overnight.
Up more than 120% year-to-date! Sea rose more than 10% on the 3rd day, with many major banks setting a high target price of $96; the two-year cumulative increase is as high as 490%! Palantir's overnight stock price hit another record high, rising more than 25% since its inclusion in the s&p 500 index announcement.
Express News | Regeneron Pharmaceuticals Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $1077 From $1175
Regeneron Stock Slides After Court Rejects Injunction Against Eye Drug Biosimilar, Truist Says